Skip to main content

From the helm: Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer

Jessica Amir
February 5, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.

Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.

In this video James discusses:

  • (0:31) What CYC does & its “imminent” entry into the US
  • (1:11) Key catalysts to drive share price growth – (1:47) Commercialising the product in the US
  • (2:46) CYC’s product being endorsed to help fight COVID-19 in the US – (3:31) How the company has reduced its risks
  • (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

Morning Bell 13 August

Bell Direct
August 13, 2024

Morning Bell 12 August

Grady Wulff
August 12, 2024

Weekly Wrap 9 August

Grady Wulff
August 9, 2024

Morning Bell 9 August

Sam Kanaan
August 9, 2024

Morning Bell 8 August

Bell Direct
August 8, 2024

Morning Bell 31 July

Sam Kanaan
July 31, 2024

Morning Bell 30 July

Sam Kanaan
July 30, 2024

Morning Bell 29 July

Grady Wulff
July 29, 2024

Weekly Wrap 26 July

Grady Wulff
July 26, 2024

Morning Bell 26 July

Sam Kanaan
July 26, 2024

Morning Bell 25 July

Grady Wulff
July 25, 2024